

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5775684

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
THIRD EYE CAPITAL CORPORATION	09/26/2019
RECEIVING PARTY DATA	
Name:	RESVERLOGIX CORP.
Street Address:	300, 4820 RICHARD ROAD SW
City:	CALGARY, AB
State/Country:	CANADA
Postal Code:	T3E 6L1
PROPERTY NUMBERS Total: 19	
Property Type	Number
Application Number:	15669219
Application Number:	15668542
Patent Number:	10016426
Patent Number:	10111885
Patent Number:	10131640
Patent Number:	9199990
Patent Number:	8884046
Patent Number:	9610251
Patent Number:	9757368
Patent Number:	9238640
Patent Number:	8889698
Patent Number:	8952021
Patent Number:	8242144
Patent Number:	8114995
Patent Number:	8242130
Patent Number:	8410109
Patent Number:	8053440
Patent Number:	8093273
Patent Number:	7846915

CORRESPONDENCE DATA**Fax Number:**

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6176461650**Email:** faxserve@finnegan.com**Correspondent Name:** FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP**Address Line 1:** 901 NEW YORK AVENUE**Address Line 4:** WASHINGTON, D.C. 20001**ATTORNEY DOCKET NUMBER:** 09741.0999-00000**NAME OF SUBMITTER:** LESLIE A. MCDONELL**SIGNATURE:** /Leslie A McDonell/**DATE SIGNED:** 10/17/2019**Total Attachments: 28**

source=Resverlogix Payoff#page1.tif
source=Resverlogix Payoff#page2.tif
source=Resverlogix Payoff#page3.tif
source=Resverlogix Payoff#page4.tif
source=Resverlogix Payoff#page5.tif
source=Resverlogix Payoff#page6.tif
source=Resverlogix Payoff#page7.tif
source=Resverlogix Payoff#page8.tif
source=Resverlogix Payoff#page9.tif
source=Resverlogix Payoff#page10.tif
source=Resverlogix Payoff#page11.tif
source=Resverlogix Payoff#page12.tif
source=Resverlogix Payoff#page13.tif
source=Resverlogix Payoff#page14.tif
source=Resverlogix Payoff#page15.tif
source=Resverlogix Payoff#page16.tif
source=Resverlogix Payoff#page17.tif
source=Resverlogix Payoff#page18.tif
source=Resverlogix Payoff#page19.tif
source=Resverlogix Payoff#page20.tif
source=Resverlogix Payoff#page21.tif
source=Resverlogix Payoff#page22.tif
source=Resverlogix Payoff#page23.tif
source=Resverlogix Payoff#page24.tif
source=Resverlogix Payoff#page25.tif
source=Resverlogix Payoff#page26.tif
source=Resverlogix Payoff#page27.tif
source=Resverlogix Payoff#page28.tif

PAYOFF AND RELEASE

September 26, 2019

TO: Resverlogix Corp.
Resverlogix Inc.

AND TO: Borden Ladner Gervais LLP

AND TO: Vision Leader Limited

AND TO: Norton Rose Fulbright Canada LLP

RE: Payoff and Release of Credit Facility

Ladies and Gentlemen:

Reference is made to (i) that certain loan agreement dated as of May 4, 2018 (as amended, supplemented, revised, restated or replaced from time to time, including pursuant to the first amendment to the loan agreement dated April 30, 2019, the second amendment to the loan agreement dated August 4, 2019 and the third amendment to the loan agreement dated September 16, 2019, hereinafter the "Loan Agreement"), among the parties from time to time party thereto as lenders (collectively, the "Lenders" and each a "Lender"), Third Eye Capital Corporation, as administrative agent and collateral agent for the Lenders (in such capacity, the "Agent"), Resverlogix Corp., as the borrower (the "Borrower") and Resverlogix Inc., as guarantor (the "Guarantor" and together with the Borrower, collectively, the "Obligors"), and (ii) the other Loan Documents (as such term is defined in the Credit Agreement) (such Loan Documents together with the Credit Agreement, hereinafter, collectively the "Credit Documents"). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Credit Agreement.

The Borrower is entering into a secured convertible debenture investment agreement (the "Refinancing") with Vision Leader Limited, for the purpose of, among other things, repaying in full the Obligations.

Upon the Agent receiving each of the following in accordance with the terms hereof (the time at which all of the conditions in the following clauses (1) through (3) inclusively shall first be satisfied is herein referred to as the "Payoff Effective Time"): (1) the Payoff Amount (as such term is defined and as more fully set out in Schedule "A" hereto), (2) a fully executed counterpart of this payoff letter agreement (this "Payoff Letter") duly signed by each of the parties hereto, and (3) a fully executed counterpart of the blocked account agreement termination by each party thereto in the form appended hereto as Schedule "B"; the Agent agrees and confirms that (A) all Obligations under or in connection with the Credit Documents shall be paid and satisfied in full and irrevocably discharged, terminated and released, (B) all of the liens, hypothecs, mortgages and security interests in any of the assets and property of the Obligors granted to or held by the Agent pursuant to the Credit Documents as security for the Obligations (collectively the "Security") shall be forever and irrevocably satisfied, released and discharged, and (C) the Credit Documents shall terminate and be of no further force or effect, other than those provisions therein that specifically survive termination.

Further, Agent agrees to (i) discharge the registrations and publications more fully described in Schedule "C" hereto, and the Agent hereby authorizes and mandates Norton Rose Fulbright Canada LLP (or its agents) to discharge such Security, including filing any and all registerable discharges made in respect of the Security and the Obligations, including, without limitation, those registrations listed in Schedule "C" hereto, at the Obligors' sole cost and expense, (ii) return to Vision Leader Limited the original share certificates held under pledge and described in Schedule "D" hereto, (iii) deliver to the Borrower (or its counsel) a release of the Agent's interest in the intellectual property of the borrower in the form appended hereto as Schedule "E" which the Borrower shall, as its obligation, deliver to, file or register with the appropriate government offices in Canada and the United States, (iv) release all interest it may hold in all of the insurance policies of the Obligors, and (v) execute any and all discharge documentation in order to discharge all registrations and filings made by or behalf of the Agent in respect of the Security and the Obligations, provided that all expenses and costs incurred by the Agent are paid by the Borrower.

The Obligors hereby irrevocably agree to reimburse Agent for all costs and expenses and out-of-pocket filing fees incurred in connection with the matters referred to in this Payoff Letter. Each of the Obligors acknowledges that Agent's execution of and/or delivery of any documents releasing any such Security is made without recourse, representation, warranty or other assurance of any kind by Agent or any Lender as to any of their rights or in any collateral security for amounts owing under any of the Credit Documents, the condition or value of any collateral, or any other matter. The Obligors hereby confirm that the commitments of the Agent and the Lenders, if any, to make any loans or otherwise extend any further accommodation under the Credit Documents are terminated in their entirety as of the Payoff Effective Time, and, as of the Payoff Effective Time, shall have no further obligation to make any loans or to otherwise extend any further accommodation under the Credit Documents to the Obligors. Notwithstanding anything to the contrary contained herein or in any of such releases or other documents, the obligations and liabilities of the Obligors to Agent and the Lenders under or in respect of the Credit Documents insofar as such obligations and liabilities survive termination of the Credit Documents shall continue in full force and effect in accordance with their terms.

The Payoff Amount referred to above shall be received by the Agent in full in accordance with the wire instructions set forth below for same day value by no later than 2:00p.m. (Toronto time) today, failing which this Payoff Letter shall have no further force or effect unless extended in writing by the Agent in its sole and absolute discretion:

Bank: Royal Bank of Canada
200 Bay Street -- Main Floor
Toronto, Ontario M5J 2J5
Institution: 003
Branch: 00002
SWIFT: ROYCCAT2
Account No.: 00002- 4084752
Account Name: Third Eye Capital Corporation In-Trust Collections
Brookfield Place
181 Bay Street, Suite 2830
Toronto, Ontario M5J 2T3

In addition, each of the Obligors, for their own behalf and for and on behalf of each of their respective subsidiaries and affiliates (hereinafter, all such Persons collectively the "Parties"),

agree that, upon the Payoff Effective Time, all such Parties hereby irrevocably release the Agent, the Lenders, and their respective affiliates and subsidiaries and their respective officers, directors, employees, shareholders, agents and representatives, as well as their respective successors and assigns, from any and all claims, obligations, rights, causes of action, and liabilities, of whatever kind or nature, whether known or unknown, whether foreseen or unforeseen, arising on or before the date hereof, which any such Parties ever had, now have or hereafter can, shall or may have for, upon or by reason of any matter, cause or thing whatsoever, which are based upon, arise under or are related to any of the Credit Documents.

The Payoff Amount has been calculated assuming that the proceeds of all cheques, wires or similar instruments for the payment of money (collectively, "Cheques") that have been received by the Agent and credited to the Obligors' loan accounts with the Agent are good collected funds. In consideration of the Agent's release of the Security, the Obligors agree to reimburse the Agent for all losses and liabilities which the Agent may incur at any time as a result of any nonpayment, claim, refund, or chargeback of any Cheque together with any expenses or other charges incident thereto; the amount of any such losses or liabilities reimbursed hereunder shall be paid to the Agent by the Obligors within ten (10) days from the Agent's demand therefor, and the amount of such demand shall be conclusive upon the Obligors in the absence of manifest error.

This Payoff Letter shall be governed by the laws of the Province of Ontario and the federal laws of Canada applicable therein. No party may assign its rights, duties or obligations under this Payoff Letter without the prior written consent of the other parties. This Payoff Letter may be executed in any number of separate counterparts, and may be executed and delivered by facsimile, each of which shall, collectively and separately, constitute one agreement. The undersigned parties have signed below to indicate their consent to be bound by the terms and conditions of this Payoff Letter.

[signature pages follow]

Very truly yours,

AGENT:

THIRD EYE CAPITAL CORPORATION

Per:



Name: Arif N. Bhalwani

Title: Managing Director

[signatures continue on following page]

[signatures continue on following page]

RESVERLOGIX CORP.

Per: *AD Mc Caffrey*
Name:
Title:

RESVERLOGIX INC.

Per: *AD Mc Caffrey*
Name:
Title:

Schedule "B"

Blocked Account Agreement Terminations

See attached.

BLOCKED ACCOUNT TERMINATION AND RELEASE

Date: September 26, 2019

WHEREAS reference is hereby made to that certain Blocked Account Agreement (the Agreement) made as of May 4, 2018 among Resverlogix Corp. (the "Corporation"), Third Eye Capital Corporation, in its capacity as administrative agent and collateral agent (the "Secured Party"), and Bank of Montreal ("Bank"), as amended, restated or otherwise supplemented from time to time. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Agreement.


For good and valuable consideration, the parties hereto hereby agree as follows:

- 1) Notwithstanding the provisions of the Agreement, the Agreement has been terminated with effect from the date hereof and is of no further force and effect.
- 2) Bank shall have no further obligations under the Agreement and the parties hereto forever release and discharge Bank and its affiliates, officers, directors, employees, agents, mandataries and representatives, of and from any and all costs, claims, proceedings and liabilities for any act or thing done or not done on or prior to the date hereof under or in connection with the Agreement.
- 3) The Secured Party shall have no further obligations under the Agreement and the parties hereto forever release and discharge the Secured Party and its affiliates, officers, directors, employees, agents, mandataries and representatives, of and from any and all costs, claims, proceedings and liabilities for any act or thing done or not done on or prior to the date hereof under or in connection with the Agreement.
- 4) This Termination and Release may be executed in any number of counterparts and delivered by facsimile, PDF or other means of electronic transmission. Each of such counterparts shall be deemed to be an original and all of such counterparts when taken together shall be deemed to constitute one and the same document.

[signature page follows]

DATED as of the date first written above.

RESVERLOGIX CORP.

By: 
Name:
Title:

THIRD EYE CAPITAL CORPORATION

By: _____
Name: Arif N. Bhalwani
Title: Managing Director

BANK OF MONTREAL

By: _____
Name:
Title:

DATED as of the date first written above.

RESVERLOGIX CORP.

By: _____

Name:

Title:

THIRD EYE CAPITAL CORPORATION

By: _____

Name: Arif N. Bhalwani

Title: Managing Director

BANK OF MONTREAL

By: _____

Name:

Title:

DATED as of the date first written above.

RESVERLOGIX CORP.

By: _____
Name:
Title:

THIRD EYE CAPITAL CORPORATION

By: _____
Name: Arif N. Bhalwani
Title: Managing Director

BANK OF MONTREAL

By: Andrew Groll
Name: Andrew Groll
Title: Director

Schedule "E"

Intellectual Property Security Release

See attached.

RELEASE OF SECURITY IN CANADIAN INTELLECTUAL PROPERTY

Date: September 26, 2019

WHEREAS reference is hereby made to that certain Canadian Intellectual Property Security Agreement (the **Agreement**) made as of May 4, 2018 by Resverlogix Corp. (the **Corporation**) in favour of Third Eye Capital Corporation, in its capacity as administrative agent and collateral agent (the **Secured Party**), as amended, restated or otherwise supplemented from time to time. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Agreement.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Creditor hereby:

1. Fully and irrevocably releases, terminates and discharges, and reassigns to the Corporation, any and all liens, security interest, right, title and interest of the Secured Party in, to and under the Intellectual Property Collateral, without recourse or representation or warranty, express or implied, including all Intellectual Property listed on Exhibit A annexed hereto; and

2. Authorizes and requests that this Release of Security Interest in Intellectual Property be recorded at the Canadian Intellectual Property Office, the United States Patent and Trademark Office, the United States Copyright Office and any similar or equivalent office in any other jurisdiction to record this Agreement.

3. This Agreement may be delivered by facsimile, PDF or other means of electronic transmission.

[signature page follows]

DATED as of the date first written above.

THIRD EYE CAPITAL CORPORATION

By: 

Name: Arif N. Bhalwani

Title: Managing Director

Annex A

Trademarks:

Trademark Registration No.	Trademark	Country	Assignment/Ownership of Company
TMA770,456	TGF-BETA SHIELD	Canada	Resverlogix Corp. 300, 4820 Richard Road SW Calgary, AB T3E 6L1
TMA770,617	TGF- β SHIELD & Design	Canada	Resverlogix Corp. 300, 4820 Richard Road SW Calgary, AB T3E 6L1
TMA769,991	CLEARING THE PATH TO BETTER HEALTH	Canada	Resverlogix Corp. 300, 4820 Richard Road SW Calgary, AB T3E 6L1
TMA799,726	RESVERLOGIX	Canada	Resverlogix Corp. 300, 4820 Richard Road SW Calgary, AB T3E 6L1
TMA710,024	TGF β -SHIELD & Design	Canada	Resverlogix Inc. 300, 4820 Richard Road SW Calgary, AB T3E 6L1
TMA709,963	NEXVAS	Canada	Resverlogix Corp. 300, 4820 Richard Road SW Calgary, AB T3E 6L1
9677964	RESVERLOGIX	European Union	Resverlogix Corp. 202, 279 Midpark Way S.E. Calgary, AB T2X1M2
4,072,774	RESVERLOGIX	U.S.A.	Resverlogix Corp. 300, 4820 Richard Road SW Calgary, AB T3E 6L1

Patents:

Flavonoids and Isoflavanoids for the Prevention and Treatment of Cardiovascular Diseases

Resverlogix Ref. No.	Country	Patent details
22981-14 US	United States	Patent No. 8,093,273 Issued 10-Jan-12; Expires 12-Nov-28
22981-14 D1	United States	Patent No. 8,242,130 Issued 14-Aug-12; Expires 24-Aug-27
22981-14 CA	Canada	Patent No. 2,584,507 Issued 26-Apr-16; Expires 20-Oct-25
22981-14 EP	Europe	Patent No. 1838296 Issued 08-Aug-12; Expires 20-Oct-25 Validated in: CH, DE, FR, GB, IE, and IT

Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases

Resverlogix Ref. No.	Country	Patent details
22981-15 US	United States	Patent No. 7,846,915 Issued 07-Dec-10; Expires on 18-Oct-27
22981-15 D1	United States	Patent No. 8,242,144 Issued 14-Aug-12; Expires 20-Oct-25
22981-15 CA	Canada	Patent No. 2,584,485 Issued 31-Dec-13; Expires 20-Oct-25

Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices

Resverlogix Ref. No.	Country	Patent details
-----------------------------	----------------	-----------------------

Resverlogix Ref. No.	Country	Patent details
22981-16 US	United States	Patent No. 8,410,109 Issued 02-Apr-13; Expires 10-Sep-26
22981-16 AU	Australia	Patent No. 2006275514 Issued 19-Jul-12; Expires 28-Jul-26
22981-16 CA	Canada	Patent No. 2,617,213 Issued 28-Jan-14; Expires 28-Jul-26
22981-16 CN	China	Patent No. ZL200680034234.1 Issued 22-May-13; Expires 28-July-26
22981-16 EP D1	Europe	Patent No. 2314295 Issued 28-Jan-15; Expires 28-Jul-26 Validated in: DE and GB
22981-16 IN	India	Patent No. 264416 Issued 29-Dec-14; Expires 28-Jul-26
22981-16 JP	Japan	Patent No. 5368792 Issued 20-Sep-13; Expires 28-Jul-26
22981-16 KR	Korea	Patent No. 1431279 Issued 11-Aug-14; Expires 28-Jul-26
22981-16 MX	Mexico	Patent No. 312991 Issued 04-Sept-13; Expires 28-Jul-26
22981-16 NZ	New Zealand	Patent No. 566180 Issued 08-Aug-11; Expires 28-Jul-26

Compounds for the Prevention and Treatment of Cardiovascular Disease

Resverlogix Ref. No.	Country	Patent details
---------------------------------	----------------	-----------------------

22981-18 US	United States	Patent No. 8,053,440 Issued 08-Nov-11; Expires 12-Aug-30
22981-18 D1	United States	Patent No. 8,889,698 Issued 18-Nov-14; Expires 01-Feb-27
22981-18 D2	United States	Patent No. 9,199,990 Issued 01-Dec-15; Expires 01-Feb-27
22981-18 D4	United States	Application No. 15/710,200

Compounds for the Prevention and Treatment of Cardiovascular Disease

Resverlogix Ref. No.	Country	Patent details
22981-19 AU	Australia	Patent No. 2007345526 Issued 15-Jun-13; Expires 01-Feb-27
22981-19 CA	Canada	Patent No. 2,676,984 Issued 17-Mar-15; Expires 01-Feb-27
22981-19 CN	China	Patent No. 200780052349.8 Issued 17-Jul-13; Expires 01-Feb-27
22981-19 EP	Europe	Patent No. 2118074 Issued 22-Jan-14; Expires 01-Feb-27 Validated in: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, UK, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, and TR
22981-19 HK	Hong Kong	Patent No. HK1136283 Issued 27-Dec-13; Expires 01-Feb-27
22981-19 HK DIV	Hong Kong	Patent No. HK1185345 Issued 10-Feb-17; Expires 01-Feb-27
22981-19 IN	India	Patent No. 277244 Issued 16-Nov-16; Expires 01-Feb-27

Resverlogix Ref. No.	Country	Patent details
22981-19 JP	Japan	Patent No. 5236664 Issued 05-Apr-13; Expires 01-Feb-27
22981-19 KR	Korea	Patent No. 1444489 Issued 18-Sep-14; Expires 01-Feb-27
22981-19 MO	Macau	Patent No. J/002184 Issued 24-Aug-16; Expires 01-Feb-27
22981-19 MX	Mexico	Patent No. 300315 Issued 15-Jun-12; Expires 01-Feb-27
22981-19 CN DIV	China	Patent No. 201310229315.9 Issued 13-Apr-16; Expires 01-Feb-27
22981-19 MX DIV	Mexico	Patent No. 341422 Issued 19-Aug-16; Expires 01-Feb-27
22981-19 MX DIV 2	Mexico	Application No. MX/a/2016/002305
22981-19 NZ	New Zealand	Patent No. 579355 Issued 09-Jul-12; Expires 01-Feb-27
22981-19 NZ DIV	New Zealand	Patent No. 597776 Issued 02-Jul-13; Expires 01-Feb-27

Methods of Preparing Quinazolinone Derivatives

Resverlogix Ref. No.	Country	Patent details
22981-21 AU	Australia	Patent No. 2009262252 Issued 15-Aug-13; Expires 24-Jun-29
22981-21 CA	Canada	Patent No. 2,711,103 Issued 09-Aug-16; Expires 24-Jun-29

Resverlogix Ref. No.	Country	Patent details
22981-21 CN	China	Patent No. ZL 2009 8 0106586.7 Issued 28-May-14; Expires 24-Jun-29
22981-21 EP	Europe	Patent No. 2346837 Issued 4-Mar-15; Expires 24-Jun-29 Validated in: CY, CZ, HR, HU, IS, MK, MT, PL, PT, SI, SK, TR, AT, BE, BG, CH, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LT, LU, LV, MC, NL, NO, RO, and SE
22981-21 HK	Hong Kong	Patent No. 1160135 Issued 23-Oct-15; Expires 24-Jun-29
22981-21 IN	India	Application No. 2335/KOLNP/2010 Published 25-Nov-11 as 2335/KOLNP/2010
22981-21 IL	Israel	Patent No. 206544 Issued 1-Nov-14; Expires 24-Jun-29
22981-21 JP	Japan	Patent No. 5602728 Issued 29-Aug-14; Expires 24-Jun-29
22981-21 KR	Korea	Patent No. 10-1629356 Issued 03-Jun-16; Expires 24-Jun-29
22981-21 MX	Mexico	Patent No. 327235 Issued 23-Jan-15; Expires 24-Jun-29
22981-21 NZ	New Zealand	Patent No. 586440 Issued 07-Nov-11; Expires 24-Jun-29
22981-21 RU	Russian Federation	Patent No. 2520098 Issued 21-Apr-14; Expires 24-Jun-29
22981-21 US	United States	Patent No. 8,114,995 Issued 14-Feb-12; Expires 22-Apr-30

Compounds for the Prevention and Treatment of Cardiovascular Disease

Resverlogix Ref. No.	Country	Patent details
22981-24 AU	Australia	Patent No. 2010204106 Issued 21-Aug-14; Expires 08-Jan-30
22981-24 CA	Canada	Patent No. 2,747,417 Issued 03-Jan-17; Expires 08-Jan-30
22981-24 EP	Europe	Patent No. 2382194 Issued 12-Mar-14; Expires 08-Jan-30 Validated in: FR, DE, IE, IT, ES, CH, and UK
22981-24 EP D1	Europe	Patent No. 2660238 Issued 06-Mar-15; Expires 08-Jan-30 Validated in: CH, DE, UK, FR, ES, and IT
22981-24 JP	Japan	Patent No. 5635535 Issued 24-Oct-14; Expires 08-Jan-30
22981-24 NZ	New Zealand	Patent No. 594332 Issued 07-Jan-14; Expires 08-Jan-30
22981-24 US	United States	Patent No. 8,952,021 Issues 10-Feb-15; Expires 28-July 31

Novel Anti-Inflammatory Agents

Resverlogix Ref. No.	Country	Patent details
22981-25 AU	Australia	Patent No. 2010224523 Issued 21-Aug-14; Expires 16-Mar-30
22981-25 BR	Brazil	Application No. PI1009315-0
22981-25 CA	Canada	Application No. 2,754,509 Issued 6-Mar-18, Expires 16-Mar-203

Resverlogix Ref. No.	Country	Patent details
22981-25 CA Div	Canada	Application No. 2,892,231 Filed 18-Jan-18
22981-25 CN Div	China	Application No. 201610191878.7
22981-25 EP	Europe	Application No. 10716048.3
22981-25 HK	Hong Kong	Application No. 12101865.6 Published 24-Aug-12 as 1161112A
22981-25 IN	India	Application No. 4120/KOLNP/2011
22981-25 D1 IN	India	Application No. 201838003240
22981-25 D2 IN	India	Application No. 201838003241
22981-25 D3 IN	India	Application No. 201838003242
22981-25 IL	Israel	Application No. 215194
22981-25 IL DIV	Israel	Application No. 230542
22981-25 JP	Japan	Patent No. 5795304 Issued 21-Aug-15; Expires 16-Mar-30
22981-25 JP DIV	Japan	Patent No. 6140226 Issued 12-May-17; Expires 16-Mar-30
22981-25 JP DIV2	Japan	Application No. 2017-089784
22981-25 KR	Korea	Patent No. 10-1709492 Issued 17-Feb-17; Expires 16-Mar-30
22981-25 KR DIV	Korea	Application No. 10-2016-7019728

Resverlogix Ref. No.	Country	Patent details
22981-25 KR DIV2	Korea	Patent No. 10-1803269 Issued 24-Nov-17; Expires 16-Mar-30
22981-25 KR DIV3	Korea	Application No. KR20170132350
22981-25 MX	Mexico	Patent No. 337352 Issued 29-Feb-16; Expires 16-Mar-30
22981-25 MX DIV	Mexico	Application No. MX/a/2015/010177
22981-25 NZ	New Zealand	Patent No. 595747 Issued 29-Sept-15; Expires 16-Mar-30
22981-25 NZ DIV	New Zealand	Patent No. 617779 Issued 01-Dec-15; Expires 16-Mar-30
22981-25 NZ DIV2	New Zealand	Patent 708314 Issued 28-Nov-17; Expires 16-Mar-30
22981-25 NZ DIV4	New Zealand	Application No. 738303
22981-25 US	United States	Patent No. 9,238,640 Issued 19-Jan-16; Expires 16-Aug-32
22981-25 US DIV	United States	Application No. 14/942,009

Novel Anti-Inflammatory Agents

Resverlogix Ref. No.	Country	Patent details
22981-26 AU	Australia	Patent No. 20100239266 Issued 07-May-15; Expires 21-Apr-30
22981-26 BR	Brazil	Application No. PI1014956-2

Resverlogix Ref. No.	Country	Patent details
22981-26 CA	Canada	Application No. 2,759,241
22981-26 CN	China	Patent No. ZI201080027599.8 Issued 23-Jun-17; Expires 21-Apr-30
22981-26 MO	Macau	Application No. J/002757
22981-26 CN DIV	China	Application No. 201710396072.6
22981-26 EP	Europe	Application No. 10714825.6
22981-26 HK	Honk Kong	Application No. 12102707.6 Published 24-Aug-12 as Publication No. 1162148A
22981-26 IN	India	Application No. 4764/KOLNP/2011
22981-26 IL	Israel	Patent No. 215799 Issued 01-Mar-15; Expires 21-Apr-30
22981-26 IL D1	Israel	Patent No. 233822 Issued 30-Jan-16; Expires 21-Apr-30
22981-26 JP	Japan	Patent No. 5813626 Issued 02-Oct-15; Expires 21-Apr-30
22981-26 KR	Korea	Application No. 2011-7027609
22981-26 MX	Mexico	Application No. MX/a/2011/011048
22981-26 MX DIV	Mexico	Application No. MX/a/2016/015962
22981-26 NZ	New Zealand	Patent No. 596117 Issued 3-Feb-15; Expires 21-Apr-30
22981-26 US	United States	Patent No. 9,757,368 Issued 12-Sep-17; Expires 21-Apr-30
22981-26 CON US	United States	Application No. 15/668,542

Resverlogix Ref. No.	Country	Patent details
22981-26 D1 US	United States	Application No. 15/669,219

Pharmaceutical Compositions for Substituted Quinazolinones

Resverlogix Ref. No.	Country	Patent details
22981-30 AU	Australia	Patent No. 2012330885 Issued 19-Jan-17; Expires 31-Oct-32
22981-30 CA	Canada	Application No. 2,851,996
22981-30 CN	China	Patent No. ZL201280053263.8 Issued 07-Sep-16; Expires 31-Oct-32
22981-30 MO	Macau	Patent No. J/002383 Issued 24-Jan-17; Expires 31-Oct-32
22981-30 EP	Europe	Application # 12844794.3 Published 10-Sep-14 as Publication No. 2773354
22981-30 HK	Hong Kong	Application No. 1201751A
22981-30 IL	Israel	Application No. 232041
22981-30 IN	India	Application No. 2751/CHEN/2014
22981-30 JP	Japan	Patent No. 5992049 Issued 26-Aug-16; Expires 31-Oct-32
22981-30 KR	Korea	Application No. 10-2014-7014790
22981-30 NZ	New Zealand	Patent No. 623381 Issued 01-Jul-16; Expires 31-Oct-32
22981-30 RU	Russia	Application No. 2014115427
22981-30 US	United States	Patent No. 9,610,251 Issued 04-Apr-17; Expires 31-Oct-32

22981-30 US DIV	United States	Application No. 15/408,814
--------------------	---------------	----------------------------

Novel Compounds Useful in the Synthesis of Benzamide Compounds

Resverlogix Ref. No.	Country	Patent details
22981-35 US	United States	Patent No. 8,884,046 Issued 11-Nov-14; Expires 09-Oct-33
22981-35 AU	Australia	Patent No. 2013333575 Issued 29-Oct-15; Expires 09-Oct-33
22981-35 BR	Brazil	Application No. BR112015008389-7
22981-35 CA	Canada	Patent No. 2,888,378 Issued 22-Sep-15; Expires 09-Oct-33
22981-35 CN	China	Patent No. ZL201380053651.0 Issued 07-Sep-16; Expires 09-Oct-33
22981-35 MO	Macau	Patent J/002372 Issued 11-Jan-17; Expires 09-Oct-33
22981-35 EP	Europe	Patent No. 2906531 Expires 09-Oct-33 Validated in: AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, NO, NL, PL, PT, RS, SE, SI and TR
22981-35 HK	Hong Kong	Application No. 15108083.4083.4
22981-35 IL	Israel	Patent No. 238186 Issued 01-Jul-16; Expires 09-Oct-33
22981-35 IL DIV	Israel	Application No. 244099
22981-35 IN	India	Application No. 1047/KOLNP/2015
22981-35 JP	Japan	Application No. 2015-536239

Resverlogix Ref. No.	Country	Patent details
22981-35 JP DIV	Japan	Application No. JP2017088632
22981-35 KR	Korea	Patent No. 10-1532570 Issued 24-Jun-15; Expires 09-Oct-33
22981-35 MX	Mexico	Patent No. 338885 Issued 04-May-16; Expires 09-Oct-33
22981-35 NZ	New Zealand	Patent No. 707276 Issued 27-May-16; Expires 09-Oct-33
22981-35 SA	Saudi Arabia	Patent No. 4770 Issued 19-Apr-16; Expires 09-Oct-33
22981-35 RU	Russia	Patent No. 2593752 Issued 15-Jul-16; Expires 09-Oct-33

Compositions and Therapeutic Methods for the Treatment of Complement-Associated Diseases

Resverlogix Ref. No.	Country	Patent details
22981-55 AR	Argentina	Application No. 20160100662
22981-55 CA	Canada	Application No. 2,977,308
22981-55 CN	China	Application No. 201680015148.X
22981-55 EP	Europe	Application No. 16764296.6
22981-55 JP	Japan	Application No. 2017-548107
22981-55 JO	Jordan	Application No. 41/2016
22981-55 KR	Korea	Application No. 10-2017-7029137
22981-55 TW	Taiwan	Application No. 105107682
22981-55 US	United States	Application No. 15/066,513

Processes for the Synthesis of 2-Amino-4, 6-Dimethoxybenzamide and Other Benzamide Compounds

Resverlogix Ref. No.	Country	Patent details	Assignment/Ownership of company
H1-7948 PCT 22981-56	PCT		IP owned by Albermarle Corp.
H1-7948 US 22981-56	United States	Patent No. 9,346,743 Issued 24-May-16; Expires 17-Oct-34	IP owned by Albermarle Corp.

Bioflavonoids as Plasma High Density Lipoprotein Level Increasing Agent

Resverlogix Ref. No.	Country	Patent details	Assignment/Ownership of company
BOK	United States	Patent No. 6,133,241 Issued 17-Oct-00; Expires 22-Oct-18	IP owned by Korea Institute of Science Technology

OTHER

None.